Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: The Swiss HIV Cohort Study

AIDS

Volumn 21, Issue 16, 2007, Pages 2201-2207

  Wolbers, Marcel ^a   Opravil, Milos ^b   Von Wyl, Viktor ^b   Hirschel, Bernard ^c   Furrer, Hansjakob ^d   Cavassini, Matthias ^e   Vernazza, Pietro ^f   Bernasconi, Enos ^g   Battegay, Manuel ^h   Yerly, Sabine ^c   Günthard, Huldrych ^b   Bucher, Heiner C ^a,h   Battegay, M ^k   Bernasconi, E ^k   Boni J ^k   Bucher, H ^k   Burgisser Ph ^k   Cattacin, S ^k   Cavassini, M ^k   Dubs, R ^k   Egger, M ^k   Elzi, L ^k   Erb, P ^k   Fischer, M ^k   Flepp, M ^k   Fontana, A ^k   Francioli, P ^e   Furrer, H ⁱ   Gorgievski, M ^k   Gunthard H ^k   Hirsch, H ^k   Hirschel, B ^k   Hosli I ^k   Kahlert, Ch ^k   Kaiser, L ^k   Karrer, U ^k   Kind, C ^k   Klimkait, Th ^k   Ledergerber, B ^k   Martinetti, G ^k   Martinez, B ^k   Muller N ^k   Nadal, D ^k   Opravil, M ^k   Paccaud, F ^k   Pantaleo, G ^k   Rickenbach, M ^j   Rudin, C ^k   Schmid, P ^k   Schultze, D ^k   Schupbach J ^k   Speck, R ^k   Taffe P ^k   Tarr, P ^k   Telenti, A ^k   Trkola, A ^k   Vernazza, P ^k   Weber, R ^k   Yerly, S ^k   more..

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^g REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ Clinical and Laboratory Committee

^j Data Center

^k NONE

more..

Author keywords

Abacavir; Cohort study; Treatment failure; Viral rebound; Viral suppression

Indexed keywords

ABACAVIR; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DRUG EXPOSURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OBSERVATIONAL STUDY; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SWITZERLAND; TREATMENT DURATION; TREATMENT FAILURE; VIRUS INACTIVATION; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; FEMALE; GENES, MDR; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SWITZERLAND; TREATMENT FAILURE; VIRAL LOAD; ZIDOVUDINE;

EID: 37348999907     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282efacb1     Document Type: Article

References (26)

1. Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave JP, Yerly S, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002; 185:1251-1260.
2. Markowitz M, Hill-Zabala C, Lang J, DeJesus E, Liao Q, Lanier ER, et al. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2005; 39:257-264.
3. Bucher HC, Kofler A, Nuesch R, Young J, Battegay M, Opravil M. Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients. AIDS 2003; 17:2451-2459.
4. Martinez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349:1036-1046.
5. Glass TR, Ungsedhapand C, Wolbers M, Weber R, Vernazza PL, Rickenbach M, et al. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med 2006; 7:404-410.
6. Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA 2001; 285:1155-1163.
7. Vibhagool A, Cahn P, Schechter M, Smaill F, Soto-Ramirez L, Carosi G, et al. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naive adults: results of a 48-week open-label, equivalence trial (CNA3014). Curr Med Res Opin 2004; 20:1103-1114.
8. Matheron S, Descamps D, Boue F, Livrozet JM, Lafeuillade A, Aquilina C, et al. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antivir Ther 2003; 8:163-171.
9. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA III, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-1861.
10. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296:827-843.
11. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - A working group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents - October 10, 2006. (www.AIDSinfo.nih.gov) [Accessed 4 August 2007].
12. Katlama C, Fenske S, Gazzard B, Lazzarin A, Clumeck N, Mallolas J, et al. TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med 2003; 4:79-86.
13. Bonjoch A, Paredes R, Galvez J, Miralles C, Videla S, Martinez E, et al. Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART. J Acquir Immune Defic Syndr 2005; 39:313-316.
14. Cozzi-Lepri A, De Luca A, Phillips AN, Bongiovanni M, Di Giambenedetto S, Mena M, et al. A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads. J Infect Dis 2006; 194:20-28.
15. Smith CJ, Phillips AN, Hill T, Fisher M, Gazzard B, Porter K, et al. The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study. J Infect Dis 2005; 192:1387-1397.
16. Yerly S, Vora S, Rizzardi P, Chave JP, Vernazza PL, Flepp M, et al. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 2001; 15:2287-2292.
17. Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 2006; 14:125-130.
18. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing (www.R-project.org) [Accessed 4 August 2007].
19. Phillips AN, Ledergerber B, Horban A, Reiss P, Chiesi A, Kirk O, et al. Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. AIDS 2004; 18:1795-1804.
20. Lanier ER, Givens N, Stone C, Griffin P, Gibb D, Walker S, et al. Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens. HIV Med 2004; 5:394-399.
21. Winston A, Mandalia S, Pillay D, Gazzard B, Pozniak A. The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients. AIDS 2002; 16:2087-2089.
22. Parikh UM, Bacheler L, Koontz D, Mellors JW. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 2006; 80:4971-4977.
23. Opravil M, Baumann D, Chave JP, Furrer H, Calmy A, Bernasconi E, et al. Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine. AIDS 2004; 18:2213-2215.
24. Martinez E, Arnaiz J, de Lazzari E, Cruceta A, Gatell JM, and NEFA Study Team. 3-year final results of a simplification trial with nevirapine, efavirenz, or abacavir as substitutes of protease inhibitors in patients with HIV infection (The NEFA study). 13th Conference on Retroviruses & Opportunistic Infections, Denver, USA, 5-8 February 2006 [abstract 521].
25. Glass TR, De Geest S, Weber R, Vernazza PL, Rickenbach M, Furrer H, et al. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2006; 41:385-392.
26. Young J, Rickenbach M, Weber R, Furrer H, Bernasconi E, Hirschel B, et al. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study. Antivir Ther 2005; 10:73-81.